CFRX ContraFect Corporation

1.00
-0.02  -2%
Previous Close 1.02
Open 1.04
Price To book 6.65
Market Cap 73449769
Shares 73,656,006
Volume 190,589
Short Ratio 2.44
Av. Daily Volume 137,363

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced May 25, 2017 - data due 4Q 2018.
CF-301
Serious infections caused byStaph aureus including MRSA

Latest News

  1. ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
  2. ContraFect to Present at 2017 World Antimicrobial Resistance Congress
  3. CFRX: Sufficient Capital To Fund Company Past Phase 2 Results for CF-301
  4. ContraFect reports 2Q loss
  5. ContraFect Announces Second Quarter 2017 Financial Results
  6. ContraFect Corporation Announces Issuance of Patent for Novel Approach to Treat Influenza Using Inhaled Antibodies
  7. CFRX: New Clinical and Microbiological Data Presented on CF-301; New Financing To Fund Company Past Phase 2 Results for CF-301
  8. ContraFect Corporation Prices $40 Million Public Offering of Common Stock and Warrants
  9. ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
  10. ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017
  11. ContraFect Chairman Steven C. Gilman Returns from Temporary Medical Leave
  12. CFRX: Phase 2 Study of CF-301 in Patients with Bacteremia Underway…
  13. ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia
  14. CFRX: Final Logistics Being Completed For Initiation of Phase 2 Trial of CF-301 in mid-2017
  15. ContraFect Announces First Quarter 2017 Financial Results
  16. ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
  17. ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
  18. CFRX: Phase 2 Trial of CF-301 to Initiate in mid-2017
  19. CORRECTION - ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update